WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 7, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation solutions
partner providing innovative products, professional education and
support for clinical science to reduce the economic and social burden of
atrial fibrillation, will release its financial results for the third
quarter of 2013 on Tuesday, October 29, 2013.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Tuesday, October 29, 2013 to discuss its third quarter 2013 financial
results. A live webcast of the conference call will be available online
from the investor relations page of AtriCure’s corporate website at www.atricure.com.
Pre-registration is available and recommended for this call at the
You may also access this call through an operator by calling (888)
713-4211 for domestic callers and (617) 213-4864 for international
callers at least 15 minutes prior to the call start time using
reservation code 83850169.
The webcast will be available on AtriCure’s website and a telephonic
replay of the call will also be available through November 29, 2013. The
replay dial-in numbers are (888) 286-8010 for domestic callers and (617)
801-6888 for international callers. The reservation code is 29085641.
About AtriCure, Inc.
AtriCure, Inc. is a leading atrial fibrillation solutions partner,
providing innovative products, professional education and support for
clinical science to reduce the economic and social burden of atrial
fibrillation. AtriCure's Synergy Ablation System is the first and only
device approved by the Food and Drug Administration (FDA) for the
surgical treatment of Persistent and Longstanding Persistent forms of
Afib in patients undergoing certain open heart procedures concomitantly
(simultaneously). AtriCure's AtriClip™ Left Atrial Appendage (LAA)
occlusion device is the most widely implanted device for LAA management
worldwide. Afib affects more than two million people worldwide and is
estimated to cost more than $6.5 billion annually in healthcare
expenses. The number affected by Afib is expected to grow to 12 million
Source: AtriCure, Inc.
Andy Wade, Vice President and Chief Financial